Abstract of GSK's drisapersen study released by TheStreet.com

An abstract that contains the results of GlaxoSmithKline's (GSK) drisapersen study, the results of which are significant for Sarepta (SRPT), was published in full in a post on TheStreet.com. The abstract says that "The continuous treatment arm showed a clinically meaningful and statistically significant difference from placebo," and that "Drisapersen may represent an important treatment option for boys with DMD having mutations correctable by exon 51 skipping." The abstract was released in a post by TheStreet's Adam Feuerstein, and The Fly notes that Feuerstein had earlier tweeted that the drisapersen data bodes well for Sarepta's eteplirsen. Shares of Sarepta spiked higher following the news, and are up $3.33, or 9.27%, to $39.17 in late afternoon trading.